Integer Holdings Corporation (ITGR)
USD 131.5
(-3.79%)
USD 131.5
(-3.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 282.05 Million USD | 19.49% |
| 2022 | 215.4 Million USD | 4.07% |
| 2021 | 215.25 Million USD | 5.06% |
| 2020 | 207.56 Million USD | -13.7% |
| 2019 | 247.49 Million USD | -3.15% |
| 2018 | 228.86 Million USD | 4.79% |
| 2017 | 190.41 Million USD | 14.15% |
| 2016 | 202.79 Million USD | 1309.2% |
| 2015 | 151.55 Million USD | -81.08% |
| 2014 | 117.57 Million USD | 25.77% |
| 2013 | 112.23 Million USD | 144.24% |
| 2012 | 71.15 Million USD | -59.67% |
| 2011 | 101.62 Million USD | 3.72% |
| 2010 | 103.64 Million USD | 244.09% |
| 2009 | 49.12 Million USD | -60.99% |
| 2008 | 92.63 Million USD | -35.86% |
| 2007 | 61.83 Million USD | -0.88% |
| 2006 | 47.44 Million USD | 90.93% |
| 2005 | 36.6 Million USD | -12.37% |
| 2004 | 41.77 Million USD | -21.15% |
| 2003 | 51.37 Million USD | 23.3% |
| 2002 | 26.66 Million USD | 16.22% |
| 2001 | 36.62 Million USD | 35.53% |
| 2000 | 27.4 Million USD | 21.14% |
| 1999 | 23.81 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 72.79 Million USD | 11.58% |
| 2024 Q2 | 87.92 Million USD | 12.81% |
| 2024 Q3 | 85.6 Million USD | 2.63% |
| 2023 Q3 | 69.4 Million USD | 3.11% |
| 2023 FY | - USD | 19.49% |
| 2023 Q4 | 68.6 Million USD | -1.16% |
| 2023 Q1 | 58.9 Million USD | 43.74% |
| 2023 Q2 | 67.31 Million USD | 14.27% |
| 2022 Q1 | 45.49 Million USD | 64.61% |
| 2022 FY | - USD | 4.07% |
| 2022 Q4 | 40.98 Million USD | -22.79% |
| 2022 Q3 | 53.07 Million USD | -10.12% |
| 2022 Q2 | 59.05 Million USD | 29.8% |
| 2021 FY | - USD | 5.06% |
| 2021 Q3 | 55.04 Million USD | -7.22% |
| 2021 Q4 | 27.63 Million USD | -49.79% |
| 2021 Q1 | 55.87 Million USD | 105.27% |
| 2021 Q2 | 59.33 Million USD | 6.19% |
| 2020 Q4 | 27.22 Million USD | -55.88% |
| 2020 Q2 | 29.01 Million USD | -55.06% |
| 2020 Q1 | 64.56 Million USD | 189.48% |
| 2020 FY | - USD | -13.7% |
| 2020 Q3 | 61.7 Million USD | 112.63% |
| 2019 Q1 | 58.66 Million USD | 49.65% |
| 2019 Q4 | 22.3 Million USD | -67.18% |
| 2019 Q2 | 72.04 Million USD | 22.81% |
| 2019 Q3 | 67.95 Million USD | -5.67% |
| 2019 FY | - USD | -3.15% |
| 2018 FY | - USD | 4.79% |
| 2018 Q4 | 39.2 Million USD | -38.53% |
| 2018 Q3 | 63.77 Million USD | 36.42% |
| 2018 Q2 | 46.74 Million USD | -28.41% |
| 2018 Q1 | 65.29 Million USD | 4.96% |
| 2017 Q2 | 29.76 Million USD | -51.27% |
| 2017 Q3 | 63.59 Million USD | 113.67% |
| 2017 Q4 | 62.2 Million USD | -2.18% |
| 2017 FY | - USD | 14.15% |
| 2017 Q1 | 61.07 Million USD | 78.67% |
| 2016 FY | - USD | 1309.2% |
| 2016 Q1 | 14.85 Million USD | 243.8% |
| 2016 Q2 | 28.59 Million USD | 92.49% |
| 2016 Q3 | 36.58 Million USD | 27.95% |
| 2016 Q4 | 34.18 Million USD | -6.57% |
| 2015 Q3 | 5.83 Million USD | -55.63% |
| 2015 Q1 | 10.94 Million USD | -39.51% |
| 2015 Q4 | -10.33 Million USD | -277.16% |
| 2015 FY | - USD | -81.08% |
| 2015 Q2 | 13.14 Million USD | 20.12% |
| 2014 Q3 | 19.95 Million USD | 3.88% |
| 2014 Q2 | 19.2 Million USD | -17.02% |
| 2014 Q1 | 23.14 Million USD | 83.75% |
| 2014 FY | - USD | 25.77% |
| 2014 Q4 | 18.08 Million USD | -9.35% |
| 2013 Q3 | 17.05 Million USD | 3.66% |
| 2013 FY | - USD | 144.24% |
| 2013 Q4 | 12.59 Million USD | -26.16% |
| 2013 Q2 | 16.45 Million USD | 17.09% |
| 2013 Q1 | 14.05 Million USD | 1026.12% |
| 2012 Q3 | 2.12 Million USD | -80.82% |
| 2012 FY | - USD | -59.67% |
| 2012 Q2 | 11.09 Million USD | -0.95% |
| 2012 Q1 | 11.19 Million USD | -54.63% |
| 2012 Q4 | 1.24 Million USD | -41.33% |
| 2011 Q3 | 12.88 Million USD | -29.58% |
| 2011 FY | - USD | 3.72% |
| 2011 Q4 | 24.68 Million USD | 91.49% |
| 2011 Q2 | 18.3 Million USD | 1.83% |
| 2011 Q1 | 17.97 Million USD | -32.4% |
| 2010 FY | - USD | 244.09% |
| 2010 Q2 | 17.32 Million USD | 23.73% |
| 2010 Q1 | 13.99 Million USD | -76.81% |
| 2010 Q4 | 26.58 Million USD | 101.83% |
| 2010 Q3 | 13.17 Million USD | -23.94% |
| 2009 Q3 | -23.91 Million USD | -291.73% |
| 2009 FY | - USD | -60.99% |
| 2009 Q4 | 60.36 Million USD | 352.45% |
| 2009 Q2 | 12.47 Million USD | -52.93% |
| 2009 Q1 | 26.49 Million USD | 19.27% |
| 2008 Q4 | 22.21 Million USD | -11.57% |
| 2008 Q3 | 25.11 Million USD | 19.5% |
| 2008 Q2 | 21.01 Million USD | 41.28% |
| 2008 Q1 | 14.87 Million USD | 22.71% |
| 2008 FY | - USD | -35.86% |
| 2007 Q1 | 11.1 Million USD | -25.16% |
| 2007 Q2 | 32.34 Million USD | 191.24% |
| 2007 Q3 | 13.55 Million USD | -58.1% |
| 2007 Q4 | 12.12 Million USD | -10.52% |
| 2007 FY | - USD | -0.88% |
| 2006 FY | - USD | 90.93% |
| 2006 Q4 | 14.83 Million USD | -11.96% |
| 2006 Q3 | 16.85 Million USD | 41.87% |
| 2006 Q1 | 14.92 Million USD | 118.47% |
| 2006 Q2 | 11.88 Million USD | -20.4% |
| 2005 FY | - USD | -12.37% |
| 2005 Q4 | 6.83 Million USD | 1.76% |
| 2005 Q3 | 6.71 Million USD | -47.0% |
| 2005 Q2 | 12.66 Million USD | 22.83% |
| 2005 Q1 | 10.31 Million USD | 30.49% |
| 2004 FY | - USD | -21.15% |
| 2004 Q3 | 8.44 Million USD | -27.17% |
| 2004 Q4 | 7.9 Million USD | -6.43% |
| 2004 Q2 | 11.59 Million USD | -14.2% |
| 2004 Q1 | 13.51 Million USD | 35.98% |
| 2003 Q1 | 13.16 Million USD | 9.8% |
| 2003 FY | - USD | 23.3% |
| 2003 Q4 | 10 Million USD | -34.73% |
| 2003 Q3 | 15.28 Million USD | 4.9% |
| 2003 Q2 | 12.94 Million USD | 10.16% |
| 2002 Q2 | 5.96 Million USD | 2.73% |
| 2002 Q1 | 8.66 Million USD | -5.54% |
| 2002 FY | - USD | 16.22% |
| 2002 Q4 | 11.25 Million USD | -9.51% |
| 2002 Q3 | 6.34 Million USD | 48.65% |
| 2001 Q1 | 8.62 Million USD | 5.84% |
| 2001 FY | - USD | 35.53% |
| 2001 Q2 | 8.42 Million USD | -2.65% |
| 2001 Q3 | 10.5 Million USD | 24.83% |
| 2001 Q4 | 9.06 Million USD | -12.88% |
| 2000 Q3 | 4.2 Million USD | 0.0% |
| 2000 Q4 | 8.39 Million USD | 98.26% |
| 2000 FY | - USD | 21.14% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 97.304% |
| Allurion Technologies Inc. | -69.03 Million USD | 508.598% |
| Artivion, Inc. | 38.14 Million USD | -639.497% |
| Avanos Medical, Inc. | 53.2 Million USD | -430.186% |
| Butterfly Network, Inc. | -124.84 Million USD | 325.929% |
| Butterfly Network, Inc. | -124.84 Million USD | 325.929% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 146.371% |
| Boston Scientific Corporation | 3.45 Billion USD | 91.831% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 2000.923% |
| CONMED Corporation | 182.18 Million USD | -54.819% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 84.043% |
| Paragon 28, Inc. | -36.61 Million USD | 870.358% |
| Glaukos Corporation | -82.11 Million USD | 443.488% |
| Globus Medical, Inc. | 418.23 Million USD | 32.56% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 1753.335% |
| Medtronic plc | 9.05 Billion USD | 96.885% |
| Nevro Corp. | -78.31 Million USD | 460.183% |
| Owlet, Inc. | -27.48 Million USD | 1126.08% |
| Penumbra, Inc. | 111.99 Million USD | -151.847% |
| Vicarious Surgical Inc. | -69.19 Million USD | 507.647% |
| Smith & Nephew plc | 979 Million USD | 71.189% |
| Sonendo, Inc. | -54.76 Million USD | 615.007% |
| STERIS plc | 1.41 Billion USD | 80.03% |
| Stryker Corporation | 5.16 Billion USD | 94.534% |
| Vapotherm, Inc. | -34.35 Million USD | 920.965% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 88.482% |